Company news

COSCIENS Biopharma Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

COSCIENS announces new corporate presentation and provides update on convertible debenture offering

October 19, 2026

COSCIENS completes second tranche of convertible debenture offering

September 16, 2026

COSCIENS acquires nualtis corp.

September 10, 2026

COSCIENS Biopharma Inc. Reports Q2 2026 Results

August 11, 2026

COSCIENS Biopharma Inc. Completes Share Capital Amendment

July 3, 2026

COSCIENS Biopharma Inc. Announces Details of Share Capital Amendment

June 22, 2026

COSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEO

June 18, 2026

COSCIENS Biopharma Inc. Reports Q1 2026 Results

May 12, 2026

COSCIENS Biopharma Inc. Provides Update on its Plan to Suspend U.S. Public Company Reporting Obligations

April 20, 2026

COSCIENS Comments on Unusual Market Activity

April 7, 2026

COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 25, 2026

COSCIENS Provides Strategic Update

March 5, 2026

COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore

December 1, 2025

COSCIENS Biopharma Inc. Announces Leadership Change

November 14, 2025

COSCIENS Biopharma Inc. Reports Third Quarter 2025 Financial Results and Provides Strategic Initiatives Update

November 11, 2025

COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update

August 14, 2025

COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders

June 30, 2025

COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders

May 30, 2025

COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders

May 26, 2025

COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

May 13, 2025

COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer

April 14, 2025

COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

April 9, 2025

COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order

April 1, 2025

COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents

March 19, 2025

COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product

March 13, 2025

JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th

January 11, 2023

JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th

January 12, 2022

CORRECTION FROM SOURCE: IIROC Trade Resumption - Aeterna Zentaris Inc.

May 1, 2017

Aeterna Zentaris Affirms Fundamental Strength of Business

November 25, 2015

Aeterna Zentaris Confirms No Corporate Developments

November 24, 2015

Aeterna Zentaris Announces Exercise of Last Series B Warrants Covered by November 1, 2015 Agreement

November 24, 2015

Aeterna Zentaris Announces First Patient Enrolled for Confirmatory Phase 3 Trial of Macrilen(TM) for the evaluation of AGHD

November 19, 2015

Aeterna Zentaris Announces Details and Implementation of Share Consolidation to Regain NASDAQ Compliance

November 18, 2015

Aeterna Zentaris Announces Shareholder Approval of Share Consolidation

November 16, 2015

Aeterna Zentaris Announces Exercise of Series B Warrants

November 12, 2015

Aeterna Zentaris Urges Shareholders to Vote in Favor of the Share Consolidation and Highlights Support from ISS and Glass Lewis

November 11, 2015

Aeterna Zentaris Reports Third Quarter Financial and Operating Results

November 5, 2015

Aeterna Zentaris Announces Agreement to Exercise Substantially All Remaining Series B Warrants

November 2, 2015

Leading Independent Advisory Firms ISS and Glass Lewis Recommend Shareholders of Aeterna Zentaris Vote FOR Share Consolidation

October 27, 2015

Aeterna Zentaris to Announce Third Quarter 2015 Financial and Operating Results on November 6, 2015

October 23, 2015

Aeterna Zentaris Announces Special Meeting of Shareholders and Mailing of Management Information Circular

October 16, 2015

Aeterna Zentaris: Data and Safety Monitoring Board Recommends Continuation of ZoptEC Phase 3 Trial in Advanced Endometrial Cancer

October 13, 2015

Aeterna Zentaris Announces Restructuring of Finance & Accounting Operations and Closure of Quebec City Office

October 12, 2015

Aeterna Zentaris' Zoptarelin Doxorubicin Meets Phase 2 Primary Endpoint in Men with Heavily Pretreated Castration and Taxane Resistant Prostate Cancer

September 28, 2015

Aeterna Zentaris Announces TSX Approval of Series B Warrant Amendment

September 25, 2015

Aeterna Zentaris Announces Dismissal of Class Action Lawsuit

September 24, 2015

Aeterna Zentaris Announces Amendment to Series B Warrants

September 21, 2015

Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York

September 3, 2015

Aeterna Zentaris Reports Second Quarter Financial and Operating Results

August 13, 2015

Aeterna Zentaris Announces Data and Safety Monitoring Board Scheduled to Complete Second Interim Analysis of the ZoptEC Phase 3 Trial in Endometrial Cancer in Early October

August 11, 2015

Older news releases →

Decks

The 5 newest of 7 decks. Every deck is listed under its year.